A Double-Blind Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

BACKGROUND: Ruxolitinib, a selective JAK1 and JAK2 inhibitor, has clinically significant activity in myelofibrosis. METHODS: In a double-blind trial, patients with intermediate-2 or high-risk myelofibrosis were randomized to twice-daily oral ruxolitinib (n=155) or placebo (n=154). The primary endpoi...

全面介紹

Na minha lista:
書目詳細資料
發表在:N Engl J Med
Main Authors: Verstovsek, Srdan, Mesa, Ruben A., Gotlib, Jason, Levy, Richard S., Gupta, Vikas, DiPersio, John F., Catalano, John V., Deininger, Michael, Miller, Carole, Silver, Richard T., Talpaz, Moshe, Winton, Elliott F., Harvey, Jimmie H., Arcasoy, Murat O., Hexner, Elizabeth, Lyons, Roger M., Paquette, Ronald, Raza, Azra, Vaddi, Kris, Erickson-Viitanen, Susan, Koumenis, Iphigenia L., Sun, William, Sandor, Victor, Kantarjian, Hagop M.
格式: Artigo
語言:Inglês
出版: 2012
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4822164/
https://ncbi.nlm.nih.gov/pubmed/22375971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1110557
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍